Features

Rising energy and raw materials costs are two key factors impacting the chemical manufacturing value chain for intermediates and small-molecule APIs. What other key developments and trends are impacting the fine-chemicals market?

With more than one month remaining in 2022, which of the bio/pharmaceutical majors are leading the pack with blockbusters (defined as products with sales of $1 billion or more)? DCAT Value Chain Insights takes an inside look.

Increased demand in biologic-based drug development is a key factor driving demand for parenteral drug manufacturing. What are key trends and expansions by CDMO/CMOs in parenteral drug manufacturing? DCAT Value Chain Insights rounds up the latest developments among CDMO/CMOs.  

Energy, inflationary pressures, and mitigating supplier risk are high priorities for Bayer. In Germany, the company aims to be independent of Russian gas by the end of the year and says that procurement management and supply chain stability are top priorities.

Although cell & gene therapies are a niche product area, the industry as a whole faces limited capacity. Both large and small CDMOs continue to expand manufacturing capacity for cell and gene therapies. Which companies are in the mix and are expanding?

The FDA is launching a Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot program to facilitate the expedited review of products with accelerated development timeframes.

The European Chemical Industry Council (Cefic) is calling for more action to address Europe’s energy crisis. For the first time ever, the EU is importing more chemicals than it exports, and Cefic is proposing specific measures to address the energy crisis and the adverse impact on chemical production.

A recent study by the management consultancy, EY, showed that a majority of supply-chain executives are focused on environmental, social and governance (ESG) initiatives, but lack capabilities to measure supply-chain sustainability. What can be done?

Medicines for Europe, which represents the generic drug industry in Europe, is calling for reforms in medicines procurement and pricing models to include security of supply as a criteria and is asking for further support for pharma manufacturing as a means to combat inflationary pressures in raw materials, transportation, and production.

A recent analysis by PwC shows that global decarbonization targets are falling short to meet net zero emissions goals, with nine of 20 major economies actually showing increases in carbon intensity over the last year. At the same time, ESG-focused institutional investment is soaring. What’s the disconnect?